Atossa Therapeutics (NASDAQ:ATOS) Announces Earnings Results

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) issued its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, Yahoo Finance reports.

Atossa Therapeutics Stock Down 8.0 %

ATOS opened at $1.84 on Wednesday. The firm has a market capitalization of $230.55 million, a P/E ratio of -7.67 and a beta of 1.19. The firm’s 50 day moving average is $1.17 and its 200-day moving average is $0.90. Atossa Therapeutics has a 52-week low of $0.59 and a 52-week high of $2.11.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Atossa Therapeutics in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a research note on Friday, January 12th. Finally, StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th.

Read Our Latest Stock Analysis on ATOS

Institutional Trading of Atossa Therapeutics

A number of hedge funds have recently made changes to their positions in the company. First Republic Investment Management Inc. grew its position in shares of Atossa Therapeutics by 79.8% during the first quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock worth $31,000 after buying an additional 11,167 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Atossa Therapeutics during the second quarter worth approximately $32,000. UBS Group AG acquired a new stake in shares of Atossa Therapeutics during the third quarter worth approximately $25,000. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the second quarter worth approximately $50,000. Finally, LPL Financial LLC acquired a new stake in shares of Atossa Therapeutics during the second quarter worth approximately $59,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Stories

Earnings History for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.